TY - JOUR
T1 - Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting:
T2 - A 24-Month, Multicenter, Non-interventional, Retrospective Study
AU - Lapolla, Annunziata
AU - Berra, Cesare
AU - Boemi, Massimo
AU - Bossi, Antonio Carlo
AU - Candido, Riccardo
AU - Di Cianni, Graziano
AU - Frontoni, Simona
AU - Genovese, Stefano
AU - Ponzani, Paola
AU - Provenzano, Vincenzo
AU - Russo, Giuseppina T
AU - Sciangula, Luigi
AU - Simioni, Natalino
AU - Bette, Cristiano
AU - Nicolucci, Antonio
PY - 2017
Y1 - 2017
N2 - INTRODUCTION:
The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice.
METHODS:
ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011.
RESULTS:
A total of 1723 patients were included in the analysis. At baseline, mean age was 58.9 years, duration of diabetes was 9.6 years, and HbA1c was 8.3%. At 12 months, 36.1% of patients were prescribed the maximum 1.8 mg dose; 43.5% [95% confidence interval (CI): 40.9; 46.2] of patients attained the primary outcome of a reduction in HbA1c of ≥ 1% point at 12 months. At 24 months, 40.9% (95% CI 38.1; 43.7) of patients had attained the HbA1c target of ≤ 7%. Additionally, body weight significantly decreased by 3.4 kg (95% CI - 3.6; - 3.1, p < 0.0001).
CONCLUSION:
In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. The data support the use of liraglutide as an effective treatment for T2D in clinical practice.
FUNDING:
Novo Nordisk S.p.A.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier, NCT02255266.
AB - INTRODUCTION:
The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice.
METHODS:
ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011.
RESULTS:
A total of 1723 patients were included in the analysis. At baseline, mean age was 58.9 years, duration of diabetes was 9.6 years, and HbA1c was 8.3%. At 12 months, 36.1% of patients were prescribed the maximum 1.8 mg dose; 43.5% [95% confidence interval (CI): 40.9; 46.2] of patients attained the primary outcome of a reduction in HbA1c of ≥ 1% point at 12 months. At 24 months, 40.9% (95% CI 38.1; 43.7) of patients had attained the HbA1c target of ≤ 7%. Additionally, body weight significantly decreased by 3.4 kg (95% CI - 3.6; - 3.1, p < 0.0001).
CONCLUSION:
In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. The data support the use of liraglutide as an effective treatment for T2D in clinical practice.
FUNDING:
Novo Nordisk S.p.A.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier, NCT02255266.
M3 - Article
JO - Advances in Therapy
JF - Advances in Therapy
SN - 0741-238X
ER -